Fig. 4: Mean change in body weight from baseline.

a Body weight change (kg) from baseline to end of treatment (Day 134), derived from mixed model for repeated measures (MMRM) analysis. Least squares mean and SE are shown. Numbers of participants (n) for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively, are as follows: BL, 37, 36, 36, 36; Day 8, 36, 36, 35, 36; Day 15, 36, 34, 35, 35; Day 22, 36, 35, 35, 36; Day 29, 36, 35, 33, 36; Day 36, 36, 33, 34, 36; Day 43, 35, 35, 35, 36; Day 50, 36, 34, 33, 36; Day 57, 36, 34, 33, 36; Day 64, 35, 34, 34, 32; Day 71, 35, 33, 32, 36; Day 78, 35, 33, 32, 34; Day 85, 35, 34, 33, 36; Day 92, 36, 34, 34, 34; Day 99, 35, 34, 33, 36; Day 106, 35, 33, 32, 34; Day 113, 36, 33, 33, 35; Day 120, 35, 33, 33, 35; Day 127, 35, 29, 33, 35; Day 134, 35, 34, 33, 33. P < 0.0001 for all ecnoglutide cohorts compared to placebo at Days 106, 120, 127, and 134. b Change in body weight compared to baseline (kg) and difference from placebo, derived from MMRM analysis. Least squares mean and SE are shown, with n = 35, 34, 33, 33 participants for the 0.4, 0.8, 1.2 mg ecnoglutide and placebo groups, respectively. Mean difference from placebo and 95% confidence interval for mean difference are indicated. P < 0.0001 for all ecnoglutide cohorts compared to placebo. c Proportion of participants with body weight loss ≥5% from baseline at Day 134. BL baseline. Source data are provided as a Source Data file.